Vermont Patent of the Month – June 2024

CoreMap, Inc. was founded to develop treatments for atrial fibrillation (AF). AF is an irregular heartbeat that can lead to blood clots, stroke, heart failure and more. This condition affects over 33 million people in the United States. In line with their mission, the company has recently been granted a patent for their cardiac mapping techniques capable of assessing fibrillation.

The company’s cardiac mapping solution significantly enhances the precision of diagnosing and treating heart arrhythmias. This advanced technique employs a two-dimensional electrode array to map the heart’s electrical activity with remarkable accuracy.

The system begins by positioning the electrode array at a strategic location in the patient’s heart. Each electrode in the array is meticulously placed and separated by known distances, allowing for simultaneous detection of local activation signals and activation times. This setup is crucial for constructing a highly detailed map of cardiac electrical activity.

One of the groundbreaking aspects of CoreMap’s method is its ability to calculate conduction velocity (CV) vectors using the activation times of multiple electrodes. By leveraging the activation times from at least three electrodes, the system can construct a precise map that pinpoints the exact location from which electrical conduction emanates within the heart. This level of detail is instrumental in identifying the specific areas responsible for arrhythmias, thereby guiding targeted ablation therapy.

Further enhancing its capabilities, the method calculates both spatial and temporal contexts for each local activation signal. This involves constructing a directed graph to identify clusters of spatio-temporally related activations and mapping the trajectory of cardiac activation waves. The system can detect conduction blocks and recalibrate the CV vectors accordingly, ensuring that the map remains accurate even in the presence of such anomalies.

CoreMap’s innovation stands out by providing a comprehensive view of the heart’s electrical landscape, revealing intricate patterns of conduction that were previously undetectable. By delivering precise, real-time data, CoreMap’s method significantly improves the success rates of ablation therapies, ultimately enhancing patient outcomes and reducing the recurrence of arrhythmias.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts